Difficulty: Medium
Average Score: 68%
Practice
Idarucizumab is used to reverse the activity of which antithrombotic drug in cases of bleeding?
Correct answer
D
Rationale
In the context of pharmacological lifespan treatment, Idarucizumab is utilized to reverse the activity of Dabigatran, making option D the correct choice in this scenario. Dabigatran is a direct thrombin inhibitor, commonly prescribed as an antithrombotic or anticoagulant medication. Idarucizumab functions as a specific antidote to Dabigatran by binding to it and neutralizing its anticoagulant effects, making it crucial in cases of severe bleeding or emergency situations where rapid reversal of Dabigatran's effects is necessary.
Regarding the other options:
- A) Dalteparin is a low molecular weight heparin and not directly reversed by Idarucizumab.
- B) Warfarin is a vitamin K antagonist and is not targeted by Idarucizumab.
- C) Alteplase is a thrombolytic agent used to break down blood clots and is not reversed by Idarucizumab.
Understanding the specific antidotes and reversal agents for different antithrombotic medications is vital in clinical practice to ensure appropriate management of complications and adverse events. This knowledge is crucial for healthcare providers, especially in emergency or critical care settings, to effectively and promptly address bleeding complications associated with anticoagulant therapy.
Regarding the other options:
- A) Dalteparin is a low molecular weight heparin and not directly reversed by Idarucizumab.
- B) Warfarin is a vitamin K antagonist and is not targeted by Idarucizumab.
- C) Alteplase is a thrombolytic agent used to break down blood clots and is not reversed by Idarucizumab.
Understanding the specific antidotes and reversal agents for different antithrombotic medications is vital in clinical practice to ensure appropriate management of complications and adverse events. This knowledge is crucial for healthcare providers, especially in emergency or critical care settings, to effectively and promptly address bleeding complications associated with anticoagulant therapy.